242 related articles for article (PubMed ID: 15574472)
1. Fluoroquinolone consumption and resistance in haematology-oncology patients: ecological analysis in two university hospitals 1999-2002.
Kern WV; Steib-Bauert M; de With K; Reuter S; Bertz H; Frank U; von Baum H
J Antimicrob Chemother; 2005 Jan; 55(1):57-60. PubMed ID: 15574472
[TBL] [Abstract][Full Text] [Related]
2. Predominance of Gram-negative bacilli and increasing antimicrobial resistance in nosocomial bloodstream infections at a university hospital in southern Taiwan, 1996-2003.
Wu CJ; Lee HC; Lee NY; Shih HI; Ko NY; Wang LR; Ko WC
J Microbiol Immunol Infect; 2006 Apr; 39(2):135-43. PubMed ID: 16604246
[TBL] [Abstract][Full Text] [Related]
3. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals.
MacDougall C; Powell JP; Johnson CK; Edmond MB; Polk RE
Clin Infect Dis; 2005 Aug; 41(4):435-40. PubMed ID: 16028149
[TBL] [Abstract][Full Text] [Related]
4. [Quinolone resistance in Gram negative rods in Iceland and association with antibiotic use].
Jónsdóttir K; Kristinsson KG
Laeknabladid; 2008 Apr; 94(4):279-85. PubMed ID: 18460726
[TBL] [Abstract][Full Text] [Related]
5. Emergence of fluoroquinolone resistance in Escherichia coli isolates at the department of clinical hematology.
Zemkova M; Kotlarova J; Merka V; Cermak P; Vlcek J; Jebavy L
New Microbiol; 2007 Oct; 30(4):423-30. PubMed ID: 18080678
[TBL] [Abstract][Full Text] [Related]
6. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution.
Cattaneo C; Quaresmini G; Casari S; Capucci MA; Micheletti M; Borlenghi E; Signorini L; Re A; Carosi G; Rossi G
J Antimicrob Chemother; 2008 Mar; 61(3):721-8. PubMed ID: 18218645
[TBL] [Abstract][Full Text] [Related]
7. [Fluoroquinolone prophylaxis utility during chemotherapy-induced severe neutropenia in patients with acute leukemia, with fluoroquinolone resistance high prevalence, in a reference hospital in Mexico City].
Ugarte-Torres A; Villasis-Keever A; Hernández-Bribiesca ME; Crespo-Solis E; Ruiz-Palacios GM; Sifuentes-Osornio J; Ponce-De-León-Garduño A
Rev Invest Clin; 2006; 58(6):547-54. PubMed ID: 17432285
[TBL] [Abstract][Full Text] [Related]
8. Influence of patient age on the frequency of occurrence and antimicrobial resistance patterns of isolates from hematology/oncology patients: report from the Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance Program (North America).
Kirby JT; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2006 Sep; 56(1):75-82. PubMed ID: 16876375
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies.
Chong Y; Yakushiji H; Ito Y; Kamimura T
Int J Infect Dis; 2011 Apr; 15(4):e277-81. PubMed ID: 21324723
[TBL] [Abstract][Full Text] [Related]
10. [Antibiotic Use at German University Hospitals (Project INTERUNI-II). Results for Medical Intensive Care, Hematology-Oncology, and Other Medical Service Areas].
de With K; Bergner J; Bühner R; Dörje F; Gonnermann C; Haber M; Hartmann M; Rothe U; Strehl E; Steib-Bauert M; Kern WV
Med Klin (Munich); 2004 Jul; 99(7):347-54. PubMed ID: 15322713
[TBL] [Abstract][Full Text] [Related]
11. Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia coli in a university hospital.
Gallini A; Degris E; Desplas M; Bourrel R; Archambaud M; Montastruc JL; Lapeyre-Mestre M; Sommet A
J Antimicrob Chemother; 2010 Dec; 65(12):2650-7. PubMed ID: 20876240
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and antibiotic sensitivity of Danish versus other European bacterial isolates from intensive care and hematology/oncology units.
Fomsgaard A; Høiby N; Friis HM; Gahrn-Hansen B; Kolmos HJ; Schouenborg P; Korsager B; Tvede M; Gutschik E; Bremmelgaard A
Eur J Clin Microbiol Infect Dis; 1995 Apr; 14(4):275-81. PubMed ID: 7649189
[TBL] [Abstract][Full Text] [Related]
13. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
[TBL] [Abstract][Full Text] [Related]
14. Significance of fluoroquinolone-resistant Escherichia coli in urinary tract infections.
Shigemura K; Arakawa S; Miura T; Nakano Y; Tanaka K; Fujisawa M
Jpn J Infect Dis; 2008 May; 61(3):226-8. PubMed ID: 18503177
[TBL] [Abstract][Full Text] [Related]
15. Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infection with ciprofloxacin-nonsusceptible Pseudomonas aeruginosa.
Ray GT; Baxter R; DeLorenze GN
Clin Infect Dis; 2005 Aug; 41(4):441-9. PubMed ID: 16028150
[TBL] [Abstract][Full Text] [Related]
16. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia.
Kern WV; Klose K; Jellen-Ritter AS; Oethinger M; Bohnert J; Kern P; Reuter S; von Baum H; Marre R
Eur J Clin Microbiol Infect Dis; 2005 Feb; 24(2):111-8. PubMed ID: 15714332
[TBL] [Abstract][Full Text] [Related]
17. Frequency of isolation and antimicrobial susceptibility of bacteria isolated from bloodstream infections at Children's Medical Center, Tehran, Iran, 1996-2000.
Mamishi S; Pourakbari B; Ashtiani MH; Hashemi FB
Int J Antimicrob Agents; 2005 Nov; 26(5):373-9. PubMed ID: 16213124
[TBL] [Abstract][Full Text] [Related]
18. Differences in the proportions of fluoroquinolone-resistant Gram-negative bacteria isolated from bacteraemic children with cancer in two Italian centres.
Castagnola E; Haupt R; Micozzi A; Caviglia I; Testi AM; Giona F; Parodi S; Girmenia C
Clin Microbiol Infect; 2005 Jun; 11(6):505-7. PubMed ID: 15882204
[TBL] [Abstract][Full Text] [Related]
19. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities.
Polk RE; Johnson CK; McClish D; Wenzel RP; Edmond MB
Clin Infect Dis; 2004 Aug; 39(4):497-503. PubMed ID: 15356812
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
